LMKC
HZNP

L.M. Kohn & Company’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

L.M. Kohn & Company’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,125
Closed -$246K – 259
2023
Q3 		$246K Hold
2,125
– – 0.09% 197
2023
Q2 		$219K Hold
2,125
– – 0.08% 207
2023
Q1 		$232K Hold
2,125
– – 0.1% 188
2022
Q4 		$242K Sell
2,125
-1,625
-43% -$135K 0.11% 183
2022
Q3 		$233K Hold
3,750
– – 0.11% 174
2022
Q2 		$300K Hold
3,750
– – 0.14% 168
2022
Q1 		$395K Buy
+3,750
New +$365K 0.15% 157

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

L.M. Kohn & Company's HZNP Position: Q4 2023 in Review

L.M. Kohn & Company sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,125 shares — an estimated $246K sold.

L.M. Kohn & Company first reported a position in HZNP in Q1 2022 and held it in 7 quarters. The position peaked at $395K in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • L.M. Kohn & Company reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • L.M. Kohn & Company sold 2,125 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $246K.
  • L.M. Kohn & Company first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 7 quarters.
  • L.M. Kohn & Company's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $395K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on L.M. Kohn & Company's 13F filing for Q4 2023, filed 9 Feb 2024.